Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 223, Issue 6, Pages 981-984Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa789
Keywords
COVID-19; neutrophil extracellular traps; immunothrombosis; fostamatinib
Categories
Funding
- Intramural Research Program of the National Institutes of Health Clinical Center
- Intramural Research Program of the National Institutes of Health National Heart Lung and Blood Institute
- Intramural Research Program of the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Intramural Research Program of the National Institutes of Health National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences [1FI2GM13780401]
- NHLBI
- Rigel pharmaceutical through a Cooperative Research and Development Agreement (CRADA)
Ask authors/readers for more resources
Neutrophil extracellular traps (NETs) play a role in immunothrombosis and mortality in COVID-19. The study demonstrates that R406 can inhibit NETs release and possibly mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.
Neutrophil extracellular traps (NETs) contribute to immunothrombosis and have been associated with mortality in coronavirus disease 2019 (COVID-19). We stimulated donor neutrophils with plasma from patients with COVID-19 and demonstrated that R406 can abrogate the release of NETs. These data provide evidence for how fostamatinib may mitigate neutrophil-associated mechanisms contributing to COVID-19 immunopathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
